<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33789365</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0376-2491</ISSN><JournalIssue CitedMedium="Print"><Volume>101</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Zhonghua yi xue za zhi</Title><ISOAbbreviation>Zhonghua Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Association between rare UBQLN2 variants and amyotrophic lateral sclerosis in Chinese population].</ArticleTitle><Pagination><StartPage>846</StartPage><EndPage>850</EndPage><MedlinePgn>846-850</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112137-20201015-02835</ELocationID><Abstract><AbstractText><b>Objective:</b> To explore the association between rare UBQLN2 variants and amyotrophic lateral sclerosis (ALS) in Chinese population, and the characteristic of phenotypes of their carriers. <b>Methods:</b> A total of 166 ALS patients who visited Department of Neurology of Peking University Third Hospital between January 2018 and July 2020 were recruited. The next-generation sequencing was performed to screen possible pathogenic rare variants of UBQLN2. Meanwhile, control individuals were obtained from 1000 Genome Project (2 504 samples) and an in-house whole-exome sequencing database (1 812 samples), separately. The sequence kernel association test (SKAT) and the SKAT-optimal test (SKAT-O) were used to identify the association between UBQLN2 rare variants and ALS. The clinical characteristics of rare variant carriers were analyzed. <b>Results:</b> A total of 33 familiar ALS and 133 sporadic ALS of Chinese ancestry were enrolled. Of the 166 ALS patients, 12.7% had bulbar-onset, 85.5% had limb-onset, and 5 cases were ALS with frontotemporal dementia (3.0%). The male-to-female ratio was 1.68&#x2236;1, with a mean age at symptom onset of (43.8&#xb1;12.2) years. Three possible pathogenic rare variants of UBQLN2 were detected, including c.128A&gt;G (p.Lys43Arg), c.142G&gt;T (p.Val48Leu) and c.1451T&gt;G (p.Val484Gly), and all of them were novel missense mutations. Compared with 1000 Genome Project, SKAT and SKAT-O showed a <i>P</i> value of 2.49&#xd7;10<sup>-6</sup> and 9.22&#xd7;10<sup>-7</sup>, respectively. While compared with the in-house database, SKAT and SKAT-O revealed a <i>P</i> value of 1.42&#xd7;10<sup>-3</sup> and 1.10&#xd7;10<sup>-3</sup>, respectively. Patients who carried rare UBQLN2 variants were with a higher rate of bulbar-onset (2/3 vs 19/163, <i>P</i>=0.042). <b>Conclusion:</b> Rare variants of UBQLN2 are associated with ALS in Chinese population, and mutation of UBQLN2 may be relevant to bulbar-onset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>J Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>X Y</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Y S</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>D S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>81873784</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7511141</NlmUniqueID><ISSNLinking>0376-2491</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071183">Autophagy-Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C405662">UBQLN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014452">Ubiquitins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071183" MajorTopicYN="N">Autophagy-Related Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014452" MajorTopicYN="N">Ubiquitins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x76ee;&#x7684;&#xff1a;</b> &#x63a2;&#x8ba8;UBQLN2&#x57fa;&#x56e0;&#x7f55;&#x89c1;&#x53d8;&#x5f02;&#x4e0e;&#x808c;&#x840e;&#x7f29;&#x4fa7;&#x7d22;&#x786c;&#x5316;&#xff08;ALS&#xff09;&#x53d1;&#x75c5;&#x7684;&#x76f8;&#x5173;&#x6027;&#x3002; <b>&#x65b9;&#x6cd5;&#xff1a;</b> &#x901a;&#x8fc7;&#x4e8c;&#x4ee3;&#x6d4b;&#x5e8f;&#x6280;&#x672f;&#x5bf9;2018&#x5e74;1&#x6708;&#x81f3;2020&#x5e74;7&#x6708;&#x5c31;&#x8bca;&#x4e8e;&#x5317;&#x4eac;&#x5927;&#x5b66;&#x7b2c;&#x4e09;&#x533b;&#x9662;&#x795e;&#x7ecf;&#x5185;&#x79d1;&#x7684;ALS&#x60a3;&#x8005;&#x8fdb;&#x884c;&#x57fa;&#x56e0;&#x68c0;&#x6d4b;&#xff0c;&#x7b5b;&#x9009;&#x51fa;UBQLN2&#x57fa;&#x56e0;&#x53ef;&#x80fd;&#x7684;&#x81f4;&#x75c5;&#x6027;&#x7f55;&#x89c1;&#x53d8;&#x5f02;&#xff0c;&#x5206;&#x522b;&#x4e0e;&#x56fd;&#x9645;&#x5343;&#x4eba;&#x57fa;&#x56e0;&#x7ec4;&#x8ba1;&#x5212;&#xff08;1000 Genome Project&#xff09;2 504&#x4e2a;&#x6837;&#x672c;&#x53ca;&#x56fd;&#x5185;&#x5168;&#x5916;&#x663e;&#x5b50;&#x6d4b;&#x5e8f;&#x5065;&#x5eb7;&#x5bf9;&#x7167;&#x6570;&#x636e;&#x5e93;1 812&#x4e2a;&#x6837;&#x672c;&#x6bd4;&#x5bf9;&#x5206;&#x6790;&#xff0c;&#x8fdb;&#x884c;&#x5e8f;&#x5217;&#x6838;&#x5173;&#x8054;&#x6027;&#x68c0;&#x9a8c;&#xff08;SKAT&#xff09;&#x53ca;&#x4f18;&#x5316;&#x7684;SKAT&#xff08;SKAT-O&#xff09;&#xff0c;&#x5e76;&#x5206;&#x6790;&#x5176;&#x81f4;&#x75c5;&#x6027;&#x7f55;&#x89c1;&#x53d8;&#x5f02;&#x643a;&#x5e26;&#x8005;&#x7684;&#x4e34;&#x5e8a;&#x8868;&#x578b;&#x7279;&#x70b9;&#x3002; <b>&#x7ed3;&#x679c;&#xff1a;</b> &#x5171;&#x7eb3;&#x5165;166&#x4f8b;&#x4e2d;&#x56fd;ALS&#x60a3;&#x8005;&#xff0c;&#x5bb6;&#x65cf;&#x6027;&#x75c5;&#x4f8b;33&#x4f8b;&#xff0c;&#x6563;&#x53d1;&#x6027;&#x75c5;&#x4f8b;133&#x4f8b;&#xff0c;&#x7537;&#x5973;&#x6bd4;&#x4f8b;&#x4e3a;1.68&#x2236;1&#xff0c;&#x53d1;&#x75c5;&#x5e74;&#x9f84;&#xff08;43.8&#xb1;12.2&#xff09;&#x5c81;&#xff0c;&#x7403;&#x90e8;&#x8d77;&#x75c5;&#x5360;12.7%&#xff0c;&#x80a2;&#x4f53;&#x8d77;&#x75c5;&#x5360;85.5%&#xff0c;5&#x4f8b;&#x4e3a;ALS&#x5408;&#x5e76;&#x989d;&#x989e;&#x53f6;&#x75f4;&#x5446;&#xff08;FTD&#xff09;&#xff08;3.0%&#xff09;&#x3002;&#x5171;&#x7b5b;&#x9009;&#x51fa;3&#x4e2a;UBQLN2&#x57fa;&#x56e0;&#x53ef;&#x80fd;&#x7684;&#x81f4;&#x75c5;&#x6027;&#x7f55;&#x89c1;&#x53d8;&#x5f02;&#xff0c;c.128A&gt;G&#xff08;p.Lys43Arg&#xff09;&#x3001;c.142G&gt;T&#xff08;p.Val48Leu&#xff09;&#x53ca;c.1451T&gt;G&#xff08;p.Val484Gly&#xff09;&#xff0c;&#x5747;&#x4e3a;&#x9519;&#x4e49;&#x7a81;&#x53d8;&#xff0c;&#x65e2;&#x5f80;&#x672a;&#x89c1;&#x81f4;&#x75c5;&#x6027;&#x62a5;&#x9053;&#x3002;&#x4ee5;1000 Genome Project&#x4f5c;&#x4e3a;&#x5bf9;&#x7167;&#xff0c;SKAT <i>P</i>=2.49&#xd7;10<sup>-6</sup>&#xff0c;SKAT-O <i>P</i>=9.22&#xd7;10<sup>-7</sup>&#xff1b;&#x4ee5;&#x56fd;&#x5185;&#x5168;&#x5916;&#x663e;&#x5b50;&#x6d4b;&#x5e8f;&#x5065;&#x5eb7;&#x5bf9;&#x7167;&#x6570;&#x636e;&#x5e93;&#x4f5c;&#x4e3a;&#x5bf9;&#x7167;&#xff0c;SKAT <i>P</i>=1.42&#xd7;10<sup>-3</sup>&#xff0c;SKAT-O <i>P</i>=1.10&#xd7;10<sup>-3</sup>&#xff1b;&#x643a;&#x5e26;UBQLN2&#x57fa;&#x56e0;&#x7f55;&#x89c1;&#x53d8;&#x5f02;&#x60a3;&#x8005;&#x7403;&#x90e8;&#x8d77;&#x75c5;&#x6bd4;&#x4f8b;&#x8f83;&#x5176;&#x4ed6;&#x60a3;&#x8005;&#x9ad8;&#xff08;2/3&#x6bd4;19/163&#xff0c;<i>P</i>=0.042&#xff09;&#x3002; <b>&#x7ed3;&#x8bba;&#xff1a;</b> UBQLN2&#x57fa;&#x56e0;&#x7f55;&#x89c1;&#x53d8;&#x5f02;&#x4e0e;ALS&#x53d1;&#x75c5;&#x5b58;&#x5728;&#x76f8;&#x5173;&#x6027;&#xff0c;&#x8be5;&#x57fa;&#x56e0;&#x7a81;&#x53d8;&#x53ef;&#x80fd;&#x4e0e;&#x7403;&#x90e8;&#x8d77;&#x75c5;&#x76f8;&#x5173;&#x3002;.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>31</Day><Hour>22</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33789365</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112137-20201015-02835</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>